Research Analysts Offer Predictions for CAPR FY2025 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at B. Riley reduced their FY2025 earnings per share (EPS) estimates for Capricor Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. B. Riley analyst M. El-Saadi now forecasts that the biotechnology company will post earnings of ($2.03) per share for the year, down from their previous forecast of ($1.85). The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Several other equities research analysts also recently weighed in on CAPR. Roth Capital raised their price target on Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target on shares of Capricor Therapeutics in a report on Thursday, September 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.38.

Capricor Therapeutics Stock Down 2.0%

Shares of Capricor Therapeutics stock traded down $0.11 during trading on Friday, reaching $5.66. The company’s stock had a trading volume of 233,004 shares, compared to its average volume of 1,831,244. Capricor Therapeutics has a 1-year low of $5.43 and a 1-year high of $20.75. The company has a 50-day simple moving average of $6.54 and a two-hundred day simple moving average of $8.24. The company has a market cap of $258.58 million, a price-to-earnings ratio of -3.45 and a beta of 0.58.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after buying an additional 2,314 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 2,786 shares during the period. Deutsche Bank AG boosted its position in shares of Capricor Therapeutics by 10.9% during the 1st quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock valued at $272,000 after acquiring an additional 2,822 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Capricor Therapeutics by 31.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 3,162 shares during the period. Finally, Legal & General Group Plc increased its position in Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 3,205 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.